-DOCSTART- -X- O
Considerable -X- _ O
interest -X- _ O
in -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
rituximab -X- _ B-Intervention
( -X- _ I-Intervention
a -X- _ I-Intervention
monoclonal -X- _ I-Intervention
CD20 -X- _ I-Intervention
antibody -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
systemic -X- _ I-Patient
lupus -X- _ I-Patient
erythematosus -X- _ I-Patient
( -X- _ I-Patient
SLE -X- _ I-Patient
) -X- _ I-Patient
has -X- _ O
been -X- _ O
generated -X- _ O
due -X- _ O
to -X- _ O
its -X- _ O
unique -X- _ O
mode -X- _ O
of -X- _ O
action -X- _ O
, -X- _ O
culminating -X- _ O
in -X- _ O
a -X- _ O
series -X- _ O
of -X- _ O
randomized -X- _ O
and -X- _ O
open -X- _ O
trials -X- _ O
, -X- _ O
and -X- _ O
case -X- _ O
reports. -X- _ O
However -X- _ O
, -X- _ O
this -X- _ O
use -X- _ O
is -X- _ O
off- -X- _ O
license -X- _ O
and -X- _ O
two -X- _ O
significant -X- _ O
RCTs -X- _ O
have -X- _ O
reported -X- _ O
negative -X- _ B-Outcome
findings -X- _ I-Outcome
, -X- _ O
reopening -X- _ O
the -X- _ O
debate -X- _ O
on -X- _ O
clinical -X- _ O
benefit. -X- _ O
This -X- _ O
review -X- _ O
of -X- _ O
the -X- _ O
available -X- _ O
data -X- _ O
suggests -X- _ O
that -X- _ O
rituximab -X- _ B-Outcome
induces -X- _ I-Outcome
B-cell -X- _ I-Outcome
depletion -X- _ I-Outcome
in -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
disease -X- _ I-Outcome
activity -X- _ I-Outcome
is -X- _ I-Outcome
achieved -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
relatively -X- _ I-Outcome
good -X- _ I-Outcome
safety -X- _ I-Outcome
profile -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
SLE -X- _ I-Outcome
. -X- _ O

